C.R. Bard’s Outperform Rating Reaffirmed at Raymond James (BCR)
Shares of C.R. Bard (NYSE: BCR) traded down 0.47% during mid-day trading on Thursday, hitting $100.33. C.R. Bard has a one year low of $93.69 and a one year high of $108.31. The stock’s 50-day moving average is currently $100.2. The company has a market cap of $8.206 billion and a P/E ratio of 16.36.
C.R. Bard (NYSE: BCR) last posted its quarterly earnings results on Thursday, January 31st. The company reported $1.70 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.67 by $0.03. The company had revenue of $762.60 million for the quarter, compared to the consensus estimate of $757.49 million. During the same quarter in the previous year, the company posted $1.70 earnings per share. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. Analysts expect that C.R. Bard will post $6.28 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of C.R. Bard in a research note to investors on Wednesday, March 13th. They now have a $106.00 price target on the stock. Separately, analysts at Northland Securities reiterated a “market perform” rating on shares of C.R. Bard in a research note to investors on Friday, March 8th. They now have a $111.00 price target on the stock. Finally, analysts at Northland Capital raised their price target on shares of C.R. Bard from $105.00 to $111.00 in a research note to investors on Friday, March 8th. They now have a “market perform” rating on the stock.
Three analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $105.43.
C. R. Bard, Inc. (NYSE: BCR) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.